Drug Database
ME

measles vaccine (live-attenuated)

✓ Approved

Beijing Tiantan Biological Products · 疫苗 · 疫苗

什么是 measles vaccine (live-attenuated)?

measles vaccine (live-attenuated) 是一种疫苗,由Beijing Tiantan Biological Products研发。该药已获批,用于治疗相关适应症,给药途径:Unknown。

药物档案

公司Beijing Tiantan Biological Products
药物类别疫苗, 大分子
给药途径Unknown
状态Approved

治疗适应症

measles vaccine (live-attenuated) 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsMeasles✓ Approved

相关研究文献

PubMedmBio2026-09-10

Targeting conserved interaction surfaces of alphavirus nsP4 supports the rational design of live-attenuated vaccine candidates.

Yang Xiaoyao X, Väljaots Evelin E, Li Kaiyu K, Naumenko Krystyna K et al.

Alphaviruses are emerging arboviruses that pose a growing threat to global public health; however, effective interventions remain limited. Recent structural studies of the chikungunya virus (CHIKV) replicase core revealed that the viral RNA-dependent RNA polymerase nsP4 interacts with both nsP1 and nsP2 and is predicted to engage viral RNA. The conservation and multifunctionality of nsP4 make it a challenging but promising target for rational attenuation. Here, we evaluated 58 structure-guided mutations in nsP4 predicted to disrupt interactions with nsP1, nsP2, or viral RNA using a trans-replicase system. Sixteen selected mutations were further analyzed in a CHIKV-o'nyong-nyong virus chimera and Semliki Forest virus (SFV). Most mutants were viable but showed varying degrees of attenuation in mammalian and mosquito cells. Viruses carrying mutations in predicted RNA-interaction sites frequently acquired pseudoreversions and/or second-site compensatory changes, whereas those harboring mutations affecting nsP1 or nsP2 interfaces were more genetically stable. Three substitutions representing defects in nsP1 interaction (F164A), predicted RNA interaction (K174S), and nsP2 interaction (D393A) were further characterized in authentic CHIKV and displayed attenuation consistent with that observed in SFV. In vivo, all three variants showed reduced pathogenicity in the SFV mouse model, with F164A being avirulent, immunogenic, and conferring complete protection against lethal challenge. In a CHIKV mouse model, these mutations attenuated disease and reduced serum virus titers and inflammatory cell infiltration. Together, these findings provide a molecular framework for the rational design of live-attenuated alphavirus vaccine candidates and support broader evaluation of nsP4-based attenuation. Alphaviruses are an increasing global health concern, with hundreds of thousands of chikungunya cases reported worldwide in 2025; however, vaccine options remain limited, and no specific antiviral treatment is available. Recent structural studies have revealed conserved functional interfaces in the viral RNA polymerase nsP4, but their value for attenuation had not been systematically explored. Here, using structure-guided mutagenesis, validation in multiple viral systems, and in vivo analysis, we show that selected nsP4 mutations can strongly attenuate replication and pathogenicity while preserving immunogenicity. These findings identify conserved nsP4 interfaces as a shared vulnerability of alphaviruses and provide a molecular framework for the rational design of broadly applicable live-attenuated vaccines while also highlighting nsP4 as a functionally constrained target relevant to antiviral development.

PMID 42720322
阅读全文 →
PubMedMicrobiology resource announcements2026-09-10

Genomic characterization of the attenuated human cytomegalovirus strain TR-VAC developed for subviral particle vaccine production.

Schmidt Hanno H, Hewel Charlotte C, Büscher Nicole N, Linke Matthias M et al.

We report the complete genome sequence of the attenuated human cytomegalovirus strain TR-VAC, developed for subviral particle vaccine production. Oxford Nanopore duplex sequencing confirmed all engineered modifications, including UL130 repair, UL25 stop codons, ddFKBP insertion, GFP deletion, and retention of the bacterial artificial chromosome backbone, without large-scale structural rearrangements.

PMID 42720293
阅读全文 →
PubMedJournal of virology2026-09-10

Spike protein derived from an apathogenic IBV strain confers attenuated phenotype to a nephropathogenic IBV strain.

Kirk James J, Sives Samantha S, Rayment Adam A, Tappin Amber A et al.

Infectious bronchitis virus (IBV), a Gammacoronavirus, causes the economically damaging disease of poultry, infectious bronchitis. Development of IBV live attenuated vaccines (LAVs) is dependent on the supply of embryonated hens' eggs and attenuation through serial passaging, upwards of 80 times. Vaccine development needs to keep pace with IBV evolution; an issue compounded as cross protection between individual IBV serotypes is unpredictable and often limited. Rational attenuation alongside the ability to propagate LAVs in cell culture offers significant advantages in terms of adaptability, cost, and speed. Most field IBV strains exhibit restricted in vitro tropism, being unable to replicate in primary or continuous cells without serial passage and adaptation. Beaudette, an attenuated IBV strain, is capable of replication in Vero cells, an ability conferred by the spike (S) glycoprotein. In this study, utilizing a recombinant IBV based on the nephropathogenic IBV strain D388, in which the S sequence is replaced with the equivalent sequence derived from Beaudette, we determine that the Beaudette spike can confer the ability to replicate in Vero cells and Beaudette's associated attenuated in vivo phenotype to a distantly related IBV strain. Assessment of infectious progeny and viral RNA in vivo suggests that attenuation was conferred by a tissue tropism-independent molecular mechanism. Analysis of innate immune responses revealed a lower intensity and less inflammatory profile. Our findings support the use of the Beaudette S protein as an avenue for the development of rationally attenuated, cell culture-propagated rIBV vaccines and identify the S protein as a contributor to nephropathogenicity.IMPORTANCEInfectious bronchitis virus (IBV), a Gammacoronavirus of chickens, causes significant economic losses worldwide. Current live attenuated vaccines (LAVs) are generated through extensive serial passage of virulent IBV strains in specific-pathogen-free (SPF) embryonated hen's eggs, upwards of 80 passages. This process is slow, dependent on the availability of SPF embryonated eggs, and the molecular basis of attenuation remains poorly understood. Development of rationally attenuated, cell-culture-based IBV vaccines would enable more rapid responses to emerging viral variants/strains. Using a recombinant IBV, we demonstrated the spike glycoprotein from the attenuated IBV strain Beaudette can confer attenuation and the ability to replicate in Vero cells to a distantly related virulent IBV strain. Attenuation was not linked to changes in tissue tropism but was associated with altered host responses. Our research provides new insights into IBV pathogenesis and presents an avenue for rational attenuation that can be exploited for future development of cell-based IBV vaccines.

PMID 42720295
阅读全文 →
PubMedCureus2026-09-10

Recurrent Mumps in a Fully Vaccinated Young Adult With a Prior Breakthrough Infection: A Case Report.

Ramadugu Rithika R, Pidikiti Chandra Varshini CV, Cordero Peña Alesha A, Almonte Angelis A et al.

Mumps is a vaccine-preventable viral disease that typically presents with parotid gland swelling and constitutional symptoms. Although widespread immunization has substantially reduced disease incidence, outbreaks continue to occur among vaccinated populations, raising concerns regarding waning immunity and vaccine failure. Recurrent mumps following both prior natural infection and complete vaccination is uncommon and remains infrequently reported. We describe a 21-year-old woman who presented with a four-day history of fever, malaise, myalgia, and progressive painful swelling of the left parotid gland associated with difficulty chewing and speaking. She had received two doses of measles-mumps-rubella (MMR) vaccine according to the national immunization schedule and had a documented history of mumps infection at nine years of age, occurring after she had already completed her two-dose MMR series (vaccine-breakthrough infection). Physical examination revealed tender unilateral parotid enlargement, cervical lymphadenopathy, and evidence of undernutrition with a body mass index of 16.7 kg/m². Laboratory evaluation demonstrated iron deficiency anemia. Further evaluation, including positive mumps RT-PCR and positive anti-mumps IgM serology, confirmed acute mumps infection, while investigations excluded alternative causes of parotid enlargement. The patient was managed conservatively with isolation, supportive care, nutritional supplementation, and symptomatic treatment, resulting in complete clinical recovery without complications. This case highlights that recurrent mumps can occur despite prior natural infection and complete MMR vaccination. Although waning immunity and host factors such as undernutrition may have contributed to susceptibility, a causal relationship cannot be established from a single case. Continued surveillance and awareness of breakthrough infections remain important, particularly in resource-limited settings.

PMID 42719503
阅读全文 →
PubMedJournal of the Pediatric Infectious Diseases Society2026-09-10

When Vaccination Meets Infection Prevention: National Practices for Inpatient Administration of Measles-Mumps-Rubella, Varicella, and Rotavirus Vaccines.

Altez Maria Susana Rueda MSR, Hutto Celia C, Hobby-Noland Delphene D, Song Xiaoyan X

PMID 42720270
阅读全文 →
PubMedFrontiers in immunology2026-09-10

A bivalent oral yeast vaccine displaying Nocardia seriolae FHA and LMBV MCP confers protection in largemouth bass (Micropterus salmoides).

Lu Jianfei J, Gu Boge B, Yu Pengzhen P, Chen Jiong J

Largemouth bass ranavirus (LMBV) and Nocardia seriolae are major pathogens affecting largemouth bass (Micropterus salmoides), causing significant economic losses. In this study, recombinant yeasts expressing the fibronectin-binding protein A (FHA) of N. seriolae or the major capsid protein (MCP) of LMBV were constructed using the yeast surface display (YSD) system. Based on these recombinant strains, a bivalent oral yeast-based vaccine was developed and its protective efficacy was systematically evaluated. Oral administration of the vaccine induced specific antibodies against FHA and MCP in serum, as well as increased the transcription levels of adaptive immune genes (IgM, IgT, MHC-II) and innate immune genes (IL-1β, TNF-α, IFN-1, Mx2) in the hindgut, liver, and spleen. Importantly, the bivalent oral vaccine provided significant protection against both pathogens in largemouth bass, with relative percent survival (RPS) values of 56.7% against N. seriolae and 63.3% against LMBV. Meanwhile, the oral vaccine reduced pathogen loads and alleviated histopathological lesions. In summary, these findings suggest that the bivalent oral vaccine developed in this study could serve as a promising strategy for controlling N. seriolae and LMBV infections in largemouth bass aquaculture.

PMID 42718698
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多measles vaccine (live-attenuated)